80%Confidence
0Views
FDASource
2026-04-07Date
Summary
Macleods Pharma's Class II recall for subpotent Levothyroxine tablets suggests manufacturing quality issues that could affect patient safety and regulatory compliance. This may lead to increased FDA oversight and potential market share loss in the competitive thyroid medication segment.
Actionable: Evaluate competitive positioning in thyroid medications as Macleods addresses quality control failures.
AI Confidence: 80%
Data Points
firmMACLEODS PHARMA USA, INC
classificationClass II
statusOngoing
distributionNationwide
productLevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: M
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now